Among the 122 cases, 20.5% had Triple Negative Breast Cancer (TNBC), 59.02% were HER2-negative, and 60.7% were Hormone Receptor (HR) positive. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.